🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Intermittent hepatic inflow occlusion (IHIO)

    Samsung Bioepis NL B.V.

    End Stage Liver Disease

    phase 3 other active

    1 trial

  2. Internet-based smoking treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 other completed

    1 trial

  3. JNJ-56021927

    Ningbo Cancer Hospital

    High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.

    phase 3 small molecule active

    1 trial

  4. KB803

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab)

    Arcus Biosciences

    Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

    phase 3 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, IO102-IO103

    IO Biotech

    Previously untreated, unresectable, or metastatic melanoma

    phase 3 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Samsung Bioepis NL B.V.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

  9. Kuvan®

    BioMarin Pharmaceutical Australia Pty Ltd

    Autistic Disorder

    phase 3 small molecule completed

    1 trial

  10. LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE

    Alphapharm Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  11. LIBTAYO 350 mg concentrate for solution for infusion., Vinorelbine 10 mg/ml concentrate for solution for infusion, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, THIO, Gemcitabine 1 g Powder for Solution for Infusion

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. LIPO-202

    Evofem Biosciences

    Central Abdominal Bulging

    phase 3 small molecule terminated

    2 trials

  13. LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii

    Biocodex

    Non-constipated Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  14. LY3819253

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  15. Learning Session

    BRIGHT MINDS BIOSCIENCES INC.

    Addiction

    phase 3 other completed

    1 trial

  16. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  17. Live-Attenuated influenza Vaccine(LAIV)

    BRIGHT MINDS BIOSCIENCES INC.

    Influenza

    phase 3 mab completed

    1 trial

  18. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Withdrawal

    phase 3 small molecule completed

    1 trial

  19. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule completed

    3 trials

  20. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 3 small molecule completed

    1 trial

  21. Lofexidine HCl

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 3 small molecule completed

    1 trial

  22. Losartan

    BRIGHT MINDS BIOSCIENCES INC.

    Glomerulonephritis, IGA

    phase 3 small molecule completed

    1 trial

  23. Lucentis 10 mg/ml solution for injection, Ranibizumab

    CuraTeQ Biologics s.r.o

    wet macula degeneration

    phase 3 small molecule active

    1 trial

  24. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources